. Author manuscript; available in PMC: 2023 May 15.

Published in final edited form as: Am J Clin Dermatol. 2018 Apr;19(2):181–193. doi: 10.1007/s40257-017-0320-y

Table 1.

Published clinical trial data for first-line regimens for advanced melanoma

Agent	Target	Response rate (%)	PFS	OS	Grade 3–4 toxicities (%)	References

Vemurafenib + cobimetinib	BRAF + MEK	68	Median 12.3 months	Median 22.3 months	60	PMID: 27480103
Dabrafenib + trametinib	BRAF + MEK	64–69	Median 11.0–11.4 months	Median 25.1 months, 72% 12-month OS	32–48	PMID: 26037941, 25399551
Pembrolizumab	PD-1	33–45^a	47% 6-month PFS	74% 12-month OS	10–14	PMID: 27092830, 25891173
Nivolumab	PD-1	40–44%	Median 5.1–6.9 months	73% 12-month OS	12–16	PMID: 25399552, 26027431
Ipilimumab + nivolumab	PD-1 + CTLA-4	58–61	Median 11.5 months	64% 24-month OS	54–55	PMID: 27622997, 26027431

CTLA-4 cytotoxic T-lymphocyte-associated protein 4, OS overall survival, PD-1 programmed cell death protein 1, PFS progression-free survival

Higher response rate in 123 patients with no prior treatments in a large phase I trial